Peroxisome proliferator-activated receptor γ ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines (original) (raw)
Issemann I, Green S . Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347: 645–50. ArticleCAS Google Scholar
Schoonjans K, Martin G, Staels B, Auwerx J . Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol 1997; 8: 159–66. ArticleCAS Google Scholar
Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM . Convergence of 9–cis retinoic acid and peroxisome proliferator signaling pathways through heterodimer formation of their receptors. Nature 1992; 358: 771–4. ArticleCAS Google Scholar
Kliewer SA, Lehmann JM, Milburn MV, Willson TM . The PPARs and PXRs: nuclear xenobiotic receptors that define novel hormone signaling pathways. Recent Prog Horm Res 1999; 54: 345–67. CASPubMed Google Scholar
Palmer CN, Hsu MH, Griffin HJ, Johnson EF . Novel sequence determinants in peroxisome proliferator signaling. J Biol Chem 1995; 270: 16114–21. ArticleCAS Google Scholar
Camp HS, Ren D, Leff T . Adipogenesis and fat-cell function in obesity and diabetes. Trends Mol Med 2002; 8: 442–7. ArticleCAS Google Scholar
Rangwala SM, Lazar MA . Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci 2004; 25: 331–6. ArticleCAS Google Scholar
Fauconnet S, Lascombe I, Chabannes E, Adessi GL, Desvergne B, Wahli W, et al. Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells. J Biol Chem 2002; 277: 23534–43. ArticleCAS Google Scholar
Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 1998; 4: 1046–52. ArticleCAS Google Scholar
Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, et al. Ligands for peroxisome proliferator-activated receptor-gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 1998; 95: 8806–11. ArticleCAS Google Scholar
Heaney AP, Fernando M, Melmed S . PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. J Clin Invest 2003; 111: 1381–8. ArticleCAS Google Scholar
Takahashi N, Okumura T, Motomura W, Fujimoto Y, Kawabata I, Kohgo Y . Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett 1999; 455: 135–9. ArticleCAS Google Scholar
Guan YF, Zhang YH, Breyer RM, Davis L, Breyer MD . Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia 1999; 1: 330–9. ArticleCAS Google Scholar
Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, Campbell N, et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 1999; 96: 3951–6. ArticleCAS Google Scholar
Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, et al. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA 2000; 97; 10990–5. ArticleCAS Google Scholar
Golimbu M, Joshi P, Sperber A, Tessler A, Al-Askari S, Morales P . Renal cell carcinoma: survival and prognostic factors. Urology 1986; 27: 291–301. ArticleCAS Google Scholar
Flanigan RC, Campbell SC, Clark JI, Picken MM . Metastatic renal cell carcinoma. Curr Treat Options Oncol 2003; 4: 385–90. Article Google Scholar
Guan Y, Zhang Y, Schneider A, Davis L, Breyer RM, Breyer MD . Peroxisome proliferator-activated receptor-gamma activity is associated with renal microvasculature. Am J Physiol Renal Physiol 2001; 281: 1036–46. Article Google Scholar
Motomura W, Okumura T, Takahashi N, Obara T, Kohgo Y . Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human pancreatic carcinoma cells. Cancer Res 2000; 60: 5558–64. CASPubMed Google Scholar
Hashimoto Y, Shimada Y, Itami A, Ito T, Kawamura J, Kawabe A, et al. Growth inhibition through activation of peroxisome proliferator-activated receptor gamma in human oesophageal squamous cell carcinoma. Eur J Cancer 2003; 39: 2239–46. ArticleCAS Google Scholar
Inoue K, Kawahito Y, Tsubouchi Y, Kohno M, Yoshimura R, Yoshikawa T, et al. Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists. Biochem Biophys Res Commun 2001; 287: 727–32. ArticleCAS Google Scholar
Heaney AP, Fernando M, Yong WH, Melmed S . Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med 2002; 8: 1281–7. ArticleCAS Google Scholar
Mossner R, Schulz U, Kruger U, Middel P, Schinner S, Fuzesi L, et al. Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma. J Invest Dermatol 2002; 119: 576–82. ArticleCAS Google Scholar
Brockman JA, Gupta RA, Dubois RN . Activation of PPARgamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 1998; 115: 1049–55. ArticleCAS Google Scholar
Luo Y, Hurwitz J, Massague J . Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature 1995; 375: 159–61. ArticleCAS Google Scholar
Pines J . Four-dimensional control of the cell cycle. Nat Cell Biol 1999; 1: 73–9. Article Google Scholar
Bartek J, Bartkova J, Lukas J . The retinoblastoma protein pathway in cell cycle control and cancer. Exp Cell Res 1997; 237: 1–6. ArticleCAS Google Scholar
Aprelikova O, Xiong Y, Liu ET . Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase. J Biol Chem 1995; 270: 18195–7. ArticleCAS Google Scholar
Shi C, Yu L, Yang F, Yan J, Zeng H . A novel organoselenium compound induces cell cycle arrest and apoptosis in prostate cancer cell lines. Biochem Biophys Res Commun 2003; 309: 578–83. ArticleCAS Google Scholar
Zhang CL, Wu LJ, Tashiro S, Onodera S, Ikejima T . Oridonin induces apoptosis of HeLa cells via altering expression of Bcl-2/ Bax and activating caspase-3/ICAD pathway. Acta Pharmacol Sin 2004; 25: 691–8. CAS Google Scholar
Filippova M, Parkhurst L, Duerksen-Hughes PJ . The human papillomavirus 16 E6 protein binds to Fas-associated death domain and protects cells from Fas-triggered apoptosis. J Biol Chem 2004; 279: 25729–44. ArticleCAS Google Scholar
Orrenius S . Mitochondrial regulation of apoptotic cell death. Toxicol Lett 2004; 149: 19–23. ArticleCAS Google Scholar
Li XH, Li JJ, Zhang HW, Sun P, Zhang YL, Cai SH, et al. Nimesulide inhibits tumor growth in mice implanted hepatoma: overexpression of Bax over Bcl-2.
Salomons GS, Brady HJ, Verwijs-Janssen M, Van Den Berg JD, Hart AA, Van Den Berg H, et al. The Bax alpha:Bcl-2 ratio modulates the response to dexamethasone in leukaemic cells and is highly variable in childhood acute leukaemia. Int J Cancer 1997; 71: 959–65. ArticleCAS Google Scholar
Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM . PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001; 7: 48–52. ArticleCAS Google Scholar
Davies GF, Khandelwal RL, Wu L, Juurlink BH, Roesler WJ . Inhibition of phosphoenolpyruvate carboxykinase (PEPCK) gene expression by troglitazone: a peroxisome proliferator-activated receptor-gamma (PPARgamma)-independent, antioxidant-related mechanism. Biochem Pharmacol 2001; 62: 1071–9. ArticleCAS Google Scholar
Wang M, Wise SC, Leff T, Su TZ . Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor-gamma. Diabetes 1999; 48: 254–60. ArticleCAS Google Scholar
Wang YL, Frauwirth KA, Rangwala SM, Lazar MA, Thompson CB . Thiazolidinedione activation of peroxisome proliferator-activated receptor gamma can enhance mitochondrial potential and promote cell survival. J Biol Chem 2002; 277: 31781–8. ArticleCAS Google Scholar
Yu C, Chen L, Luo H, Chen J, Cheng F, Gui C, et al. Binding analyses between human PPARgamma-LBD and ligands. Eur J Biochem 2004; 271: 386–97. ArticleCAS Google Scholar
Bae MA, Rhee H, Song BJ . Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines. Toxicol Lett 2003; 139: 67–75. ArticleCAS Google Scholar
Bova MP, Tam D, McMahon G, Mattson MN . Troglitazone induces a rapid drop of mitochondrial membrane potential in liver HepG2 cells. Toxicol Lett 2005; 155: 41–50. ArticleCAS Google Scholar
Tsuchiya T, Shimizu H, Shimomura K, Mori M . Troglitazone inhibits isolated cell proliferation, and induces apoptosis in isolated rat mesangial cells. Am J Nephrol 2003; 23: 222–8. ArticleCAS Google Scholar